

CLAIMS

1. An isolated crystalline form of 2-methyl-1-[(4-[6- {(trifluoromethyl)pyridin-2-yl]-6-{[2-trifluoromethyl]pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol methanesulfonate, characterized by an X-ray powder diffraction pattern having peaks at 2 θ angles of 7.5, 9.3, 14.5, 18.8, 21.3, and 24.8° $\pm$ 0.2° .
2. The isolated crystalline form of claim 1, characterized by an X-ray powder diffraction pattern substantially similar to FIGURE 5.
3. Use of the crystalline form of claim 1 or 2 in the manufacture of a medicament for treating an advanced hematologic malignancy in a subject, wherein the advanced hematologic malignancy selected from acute myelogenous leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia, myeloid sarcoma, multiple myeloma, and lymphoma, each characterized by the presence of a mutant allele of IDH2..
4. The use of claim 3, wherein the crystalline form is to be administered to the subject at a dose of 30 mg to 300 mg free-base equivalent strength, once daily or twice daily.
5. The use of claim 4, wherein the dose is about 75 mg, once daily or twice daily.
6. The use of claim 4, wherein the dose is about 100 mg, once daily or twice daily.
7. The use of claim 4, wherein the dose is about 150 mg, once daily or twice daily.
8. The use of claim 4, wherein the dose is about 200 mg, once daily or twice daily.
9. The use of any one of claims 3-8, wherein the crystalline form is to be administered as an oral dosage form.
10. The use of claim 9, wherein the oral dosage form is a tablet.
11. The use of claim 3, wherein the crystalline form is to be administered orally as any combination of 5, 10, 50, or 200 mg free-base equivalent strength tablets, twice daily or once daily.
12. The use of any one of claims 3-11, wherein the advanced hematologic malignancy is acute myelogenous leukemia.
13. The use of claim 12, wherein the acute myelogenous leukemia is relapsed or primary refractory acute myelogenous leukemia.
14. The use of any one of claims 3-11, wherein the advanced hematologic malignancy is myelodysplastic syndrome.

15. The use of any one of claims 3-11, wherein the advanced hematologic malignancy is chronic myelomonocytic leukemia.

16. The use of any one of claims 3-11, wherein the advanced hematologic malignancy is lymphoma.

17. The use of any one of claim 3-16, wherein the crystalline form is to be administered as a first line, second line, third line, or fourth line treatment for acute myelogenous leukemia.

18. A pharmaceutical composition comprising the crystalline form of claim 1 or 2 and a pharmaceutically acceptable carrier.